eHSP90α in front-line therapy in EGFR exon 19 deletion and 21 Leu858Arg mutations in advanced lung adenocarcinoma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
eHSP90α in front-line therapy in EGFR exon 19 deletion and 21 Leu858Arg mutations in advanced lung adenocarcinoma ; volume:24 ; number:1 ; day:12 ; month:7 ; year:2024 ; pages:1-13 ; date:12.2024
BMC cancer ; 24, Heft 1 (12.7.2024), 1-13, 12.2024
- Urheber
-
Bian, Yingzhen
Liu, Haizhou
Huang, Jinglei
Feng, Zhaorong
Lin, Yanyan
Li, Jilin
Zhang, Litu
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-024-12573-3
- URN
-
urn:nbn:de:101:1-2409292113427.778280355864
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:24 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bian, Yingzhen
- Liu, Haizhou
- Huang, Jinglei
- Feng, Zhaorong
- Lin, Yanyan
- Li, Jilin
- Zhang, Litu
- SpringerLink (Online service)
Ähnliche Objekte (12)
Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
Detection of internal exon deletion with exon Del
EGFR exon 20 insertion mutations in NSCLC
Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M
Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21
CRISPR/Cas9-mediated genome editing induces exon skipping by alternative splicing or exon deletion
Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy
Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study
Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation
Vergleich Gastrointestinaler Stromatumoren (GIST) mit Exon-11-Punktmutationen und Exon-11-Deletionen nach klinisch-pathologischen Parametern und Lokalisation
Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
Exons deletion of CNKSR2 gene identified in X-linked syndromic intellectual disability
Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
Detection of internal exon deletion with exon Del
EGFR exon 20 insertion mutations in NSCLC
Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M
Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21
CRISPR/Cas9-mediated genome editing induces exon skipping by alternative splicing or exon deletion
Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy
Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study
Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation
Vergleich Gastrointestinaler Stromatumoren (GIST) mit Exon-11-Punktmutationen und Exon-11-Deletionen nach klinisch-pathologischen Parametern und Lokalisation
Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
Exons deletion of CNKSR2 gene identified in X-linked syndromic intellectual disability
Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
Detection of internal exon deletion with exon Del
EGFR exon 20 insertion mutations in NSCLC
Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M
Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21
CRISPR/Cas9-mediated genome editing induces exon skipping by alternative splicing or exon deletion
Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy
Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study
Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation
Vergleich Gastrointestinaler Stromatumoren (GIST) mit Exon-11-Punktmutationen und Exon-11-Deletionen nach klinisch-pathologischen Parametern und Lokalisation
Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer